

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 August 2025 (07.08.2025)



(10) International Publication Number
WO 2025/165980 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
C07K 16/18 (2006.01) A61P 35/02 (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:

PCT/US2025/013764

(22) International Filing Date:

30 January 2025 (30.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/627,788	31 January 2024 (31.01.2024)	US
63/575,689	06 April 2024 (06.04.2024)	US
63/708,634	17 October 2024 (17.10.2024)	US
63/750,959	29 January 2025 (29.01.2025)	US

(71) Applicant: CULLINAN THERAPEUTICS, INC.

[US/US]; One Main Street, Suite 1350, Cambridge, Massachusetts 02142 (US).

(72) Inventors: JONES, Jeffery; One Main Street, Suite 1350,

Cambridge, Massachusetts 02142 (US). MICHAELSON,

Jennifer; One Main Street, Suite 1350, Cambridge, Massachusetts 02142 (US). BAEUERLE, Patrick; One Main Street, Suite 1350, Cambridge, Massachusetts 02142 (US). SHAPIRO, Irina; One Main Street, Suite 1350, Cambridge, Massachusetts 02142 (US). WAX, Steven; One Main Street, Suite 1350, Cambridge, Massachusetts 02142 (US). SREIH, Antoine; One Main Street, Suite 1350, Cambridge, Massachusetts 02142 (US). TOZZI, Brian; One Main Street, Suite 1350, Cambridge, Massachusetts 02142 (US).

(74) Agent: TYSON, Malaika, D.; LATHROP GPM LLP, 155 North Wacker Drive, Suite 3800, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: THERAPIES FOR AUTOIMMUNE DISORDERS




FIG. 1

(57) Abstract: The present invention relates methods of producing B cell depletion in autoimmune diseases. More specifically, the invention shows the use of CD-19 bispecific targeting molecules to effectively treat autoimmune disorders such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's disease (SjD).

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*